co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. More Details
+ 1 more risk
Adequate balance sheet and fair value.
Share Price & News
How has co.don's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CNWK's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CNWK underperformed the German Biotechs industry which returned -5.4% over the past year.
Return vs Market: CNWK underperformed the German Market which returned 0.1% over the past year.
Price Volatility Vs. Market
How volatile is co.don's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall Stco.don AG's (ETR:CNWK) Profit Outlook
4 months ago | Simply Wall StImagine Owning co.don (ETR:CNWK) And Trying To Stomach The 85% Share Price Drop
7 months ago | Simply Wall Stco.don AG (ETR:CNWK) Is Expected To Breakeven
Is co.don undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CNWK (€0.88) is trading below our estimate of fair value (€2.57)
Significantly Below Fair Value: CNWK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CNWK is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: CNWK is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CNWK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CNWK is good value based on its PB Ratio (1.8x) compared to the DE Biotechs industry average (3.9x).
How is co.don forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNWK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNWK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNWK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CNWK's revenue (34.2% per year) is forecast to grow faster than the German market (6% per year).
High Growth Revenue: CNWK's revenue (34.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CNWK is forecast to be unprofitable in 3 years.
How has co.don performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CNWK is currently unprofitable.
Growing Profit Margin: CNWK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CNWK is unprofitable, and losses have increased over the past 5 years at a rate of 34.8% per year.
Accelerating Growth: Unable to compare CNWK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNWK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).
Return on Equity
High ROE: CNWK has a negative Return on Equity (-85.21%), as it is currently unprofitable.
How is co.don's financial position?
Financial Position Analysis
Short Term Liabilities: CNWK's short term assets (€8.1M) exceed its short term liabilities (€4.7M).
Long Term Liabilities: CNWK's short term assets (€8.1M) exceed its long term liabilities (€3.3M).
Debt to Equity History and Analysis
Debt Level: CNWK is debt free.
Reducing Debt: CNWK had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CNWK has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CNWK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is co.don current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CNWK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CNWK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CNWK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CNWK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CNWK's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Tilmann Bur (55 yo)
Mr. Tilmann Bur has been an Additional Member of the Executive Board of co.don AG since June 1, 2019 and served as its Chief Operating Officer until January 2020. Mr. Bur is an internationally experienced ...
|Independent Member of the Supervisory Board||8.08yrs||no data||no data|
|Member of Supervisory Board||1.33yrs||no data||no data|
|Independent Member of the Supervisory Board||14.92yrs||no data||no data|
|Independent Chairman of Supervisory Board||2.83yrs||no data||no data|
|Independent Member of Supervisory Board||4.17yrs||no data||no data|
|Independent Member of the Supervisory Board||10.25yrs||no data||no data|
Experienced Board: CNWK's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 73.9%.
co.don AG's company bio, employee growth, exchange listings and data sources
- Name: co.don AG
- Ticker: CNWK
- Exchange: XTRA
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €33.435m
- Shares outstanding: 37.82m
- Website: https://www.codon.de
Number of Employees
- co.don AG
- Warthestrasse 21
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CNWK||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Feb 2001|
|CNWK||XTRA (XETRA Trading Platform)||Yes||Common Shares||DE||EUR||Feb 2001|
|0Q37||LSE (London Stock Exchange)||Yes||Common Shares||GB||EUR||Feb 2001|
|CNWKd||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||EUR||Feb 2001|
co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. The company develops, produces, and markets autologous cell therapies for the ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/24 20:38|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.